Dominic Piscitelli sold $73k of ORIC
Chief Financial Officer at Oric Pharmaceuticals, Inc.. 8,851 shares at an average of $8.28, traded Dec 16, 2024, filed Dec 17, 2024.
Score components
- +22RoleCFO
- +8Trade size$73k at market
- 0Share of holdings soldSold 7.7% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-029634, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 15, 2024 | MOption exercise Common Stock | +24,042 | $0.00 | $0 | 115,615 | Dec 17, 2024 |
| Dec 16, 2024 | SOpen-market sale Common Stock | -8,851 | $8.28 | $73k | 106,764 | Dec 17, 2024 |
| Dec 15, 2024 | MOption exercise Restricted Stock Unitderivative | -6,042 | $0.00 | $0 | 0 | Dec 17, 2024 |
| Dec 15, 2024 | MOption exercise Restricted Stock Unitderivative | -8,000 | $0.00 | $0 | 8,000 | Dec 17, 2024 |
| Dec 15, 2024 | MOption exercise Restricted Stock Unitderivative | -10,000 | $0.00 | $0 | 20,000 | Dec 17, 2024 |
Related signals
Other insiders at Oric Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 2Weak | Oric Pharmaceuticals, Inc. | Richard A. Heyman director | $87k 6,700 shares | -16% | |
| 12Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $181k 13,400 shares | -16% | |
| 0Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $8,103 600 shares | -1% | |
| 35Weak | Oric Pharmaceuticals, Inc. | Jacob Chacko PRESIDENT AND CEO | $1.3M 125,000 shares | -16% | |
| 24Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $201k 20,000 shares | -29% | |
| 27Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $351k 33,500 shares | -33% | |
| 40Moderate | ORICbuy Oric Pharmaceuticals, Inc. | Angie You director | $263k 28,000 shares | - | |
| 2Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $3,000 300 shares | -0% | |
| 8Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $33k 3,300 shares | -3% | |
| 7Weak | Oric Pharmaceuticals, Inc. | Dominic Piscitelli Chief Financial Officer | $29k 2,900 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.